Exhibit 99.1

CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES

UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

INDEX

CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2026

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS AS OF DECEMBER 31, 2025 AND JUNE 30, 2026

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2026

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR SIX MONTHS ENDED JUNE 30, 2025 AND 2026

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

Note 1 General Information

These unaudited interim condensed consolidated financial statements are the unaudited interim financial statements of CytoMed Therapeutics Limited (the “Company”) and its subsidiaries (the “Group”), for the six months ended June 30, 2026 (the “Financial Statements”).

The Company was incorporated in the Republic of Singapore on March 9, 2018. The Company is a public limited company incorporated and domiciled in Singapore with registered office situated at 1 Commonwealth Lane, #08-22, Singapore 149544. The Company is headquartered in Singapore and conducts its operations domestically and in Malaysia. The Company is listed on the Nasdaq Stock Exchange under the ticker symbol “GDTC” on April 14, 2023.

The principal activities of the Company are to carry on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy. The Company operates primarily through its wholly owned subsidiary, CytoMed Therapeutics (Malaysia) Sdn. Bhd., which is incorporated and domiciled in Malaysia. This subsidiary focuses on manufacturing innate immune cell-based immunotherapy and pluripotent stem cell-based therapy, providing consultancy services, and conducting research and development in immune cell and stem cell-based therapies to advance cellular immunotherapy for cancer treatment. Additionally, the Company is involved in cord blood banking and cord blood-derived cell therapy through its indirect subsidiary, IPSC Depository Sdn. Bhd.

The principal activities of the subsidiaries of the Company are as follows:

 Schedule of principal activities of subsidiaries

On August 22, 2025, the Company transferred its entire equity interest in Puricell Lab Pte Ltd (“Puricell Lab”) to its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) for a nominal cash consideration of S$1. As a result, the effective equity interest held in Puricell Lab diluted from 95% to 86%.

On December 26, 2025, the Company injected additional capital to its subsidiary, CytoMed Therapeutics (Malaysia) Sdn. Bhd. (“CytoMed Malaysia”) amounting approximately MYR7.5 million. As a result of this capital injection, the effective equity interest held in CytoMed Malaysia remains at 100%.

On December 12, 2025, LongevityBank issued and allotted 140,000 ordinary shares amounting to S$700,000 to a third party and a related party. As a result of this capital injection, the effective equity interest held in LongevityBank diluted from 90% to 77% whereas effective equity interest held in Puricell Lab further diluted from 86% to 73%.

On June 24, 2026, LongevityBank issued and allotted 60,000 ordinary shares amounting to S$300,000 to a related party. As a result of this capital injection, the effective equity interest held in LongevityBank diluted from 77% to 72% whereas effective equity interest held in Puricell Lab further diluted from 73% to 68%.

These activities do not result in loss of control which are accounted for as transactions with owners in their capacity as owners. The carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative ownership. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the parent.

Note 2 Summary of significant accounting policies

The unaudited condensed interim consolidated financial statements for the six-month ended June 30, 2026 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The unaudited interim consolidated financial statements do not include all the information and footnotes required by the International Financial Reporting Standards (“IFRS”) for complete financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance with the IFRS have been condensed or omitted consistent with Article 10 of Regulation S-X. In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, in normal recurring nature, as necessary for the fair statements of the Company’s financial positions as of June 30, 2026, and results of operations and cash flows for the six-month period ended June 30, 2026. The unaudited interim condensed consolidated statements of financial positions as of December 31, 2025 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by the IFRS. Interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the years ended December 31, 2025, 2024 and 2023, and related notes included in the Company’s audited consolidated financial statements.

The accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Group has adopted all the new and amended standards which are relevant to the Group and are effective for annual financial period beginning on January 1, 2026. The adoption of these standards did not have any material effect on the unaudited interim condensed consolidated financial statements of the Group.

There are a number of standards, amendments to standards, and interpretations, which have been issued by the International Accounting Standards Board, that are effective in future accounting periods and the Group has not decided to early adopt. Unless otherwise disclosed, the Group is currently evaluating the potential impact of adopting these standards on its consolidated financial statements and related disclosures in the year of initial application.

All translations from Singapore dollars to US dollars and from US dollars to Singapore dollars in this Report are made at a rate of S$1.2941 to US$1.00, the exchange rate in effect as of June 30, 2026 as set forth in the H.10 statistical release of the US Board of Governors of the Federal Reserve System.

Prudent liquidity risk management implies sufficient cash to finance the Group’s and the Company’s operations and development activities. The Group manages the liquidity risk by maintaining a level of cash and cash equivalents deemed adequate to finance the Group’s business operations and development activities. The Group’s objective is to maintain a balance between continuing of funding and flexibility through the use of borrowings.

As of June 30, 2026, the Group has negative cash flow from operating activities of S$1,645,739. The Group’s working capital was S$2,012,021. As of June 30, 2026, the Group had S$1,458,764 in cash and bank balances, which is unrestricted as to withdrawal and use as of June 30, 2026. In view of these circumstances, the management of the Group has given consideration to the future liquidity and performance of the Group and its available sources of finance in assessing whether the Group will have sufficient financial resources to continue as a going concern, at least, for the next twelve months from the date of this report.

Note 3 Significant accounting judgements and estimates

The preparation of the unaudited condensed interim consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2025.

Note 4 Segment information

The Group has identified two operating segments i.e. (i). the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy as well as (ii) the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy.

Note 5 Revenue

The Group’s revenues are primarily derived from the provision of cord blood and cells storage services (“private blood banking services”). The Company derives revenue from transfer of services over time or at a point in time in the following major type of services.

Disaggregation of revenue from contracts with customers

 Schedule of disaggregation of revenue from contracts with customers

Note 6 Other operating income

 Schedule of other operating income

Note 7 Other losses/(gains) including fair value changes on financial instruments - net

 Schedule of other (losses)/gains - net

The Group measures the warrant liabilities at fair value using Black-Scholes option pricing model.

Note 8 Research expenses

 Schedule of research expenses

Research expenses include research personnel costs, depreciation of research equipment and laboratory consumables for research activities.

Note 9 Employee benefits expenses

 Schedule of employee benefits expenses

Employee benefits are recognized as an expense, unless the cost qualifies to be capitalized as a development expenditure.

Note 10 Finance expenses

 Schedule of finance expenses

Finance expenses arising from bank borrowings and leases liabilities are presented as financing activities in the Unaudited Interim Condensed Consolidated Statements of Cash Flows.

Note 11 Other expenses

 Schedule of other expenses

Note 12 Trade and other receivables

 Schedule of trade and other receivables